Now Is the Time: Help Transform PD Treatments

Dear Friend, Transformative treatments for people with Parkinson's are closer than ever. We need your help to move them over the goal line. The Michael J. Fox Foundation (MJFF) has invested millions of research dollars into understanding LRRK2 -- a genetic mutation linked to Parkinson's disease (PD) -- and developing it as a drug target. Recently, MJFF-funded researchers made a genetic discovery with broader implications across the PD population: drugs targeting LRRK2 might also affect disease progression in people without a mutation. In the clinic, the second of two LRRK2 inhibitor drugs in development reached a major milestone this month, proving to be safe and effective in decreasing LRRK2 activity in healthy volunteers. The drug will now move into trials of Parkinson's patients with and without a LRRK2 mutation, a significant first for these therapies. Your support is critical to MJFF's sustained impact across the field. Donate today so that key scientific discoveries continue to speed toward breakthrough treatments. Thank you, The Michael J. Fox Foundation